(VKTX) Viking Therapeutics - Ratings and Ratios
Drugs, Liver, Diabetes, Obesity, Treatment
VKTX EPS (Earnings per Share)
VKTX Revenue
Description: VKTX Viking Therapeutics
Viking Therapeutics Inc (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. The companys pipeline includes several promising candidates, including VK2809, VK5211, VK0612, VK2735, and VK0214, targeting various conditions such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and X-linked adrenoleukodystrophy.
From a clinical perspective, VK2809 is in Phase IIb trials for NASH and NAFLD, while VK5211 is in Phase II trials for patients recovering from hip fracture surgery. VK2735, a dual agonist of glucagon-like peptide, is in Phase 1 SAD/MAD trials, indicating a potentially innovative approach to treating metabolic disorders. The companys diverse pipeline and progression through clinical trials suggest a strong potential for growth.
To further evaluate VKTXs potential, key performance indicators (KPIs) such as cash reserves, burn rate, and upcoming milestones can provide valuable insights. With a market capitalization of approximately $3.87 billion, Viking Therapeutics has a significant market presence. However, the absence of a P/E ratio indicates that the company is not yet profitable. Return on Equity (RoE) is -19.98%, highlighting the companys current investment phase. Investors should monitor news on clinical trial results, regulatory approvals, and strategic partnerships, as these events can significantly impact the stock price.
From a trading perspective, analyzing the stocks momentum and trends can help identify potential entry and exit points. While the current price is $32.68, with a 52-week range of $19.98 to $78.03, understanding the drivers behind these price movements is essential. Key levels of support and resistance, as well as trading volumes, should be closely watched to gauge market sentiment.
VKTX Stock Overview
| Market Cap in USD | 3,017m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2015-04-29 |
VKTX Stock Ratings
| Growth Rating | 23.4% |
| Fundamental | 19.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -70.3% |
| Analyst Rating | 4.42 of 5 |
VKTX Dividends
Currently no dividends paidVKTX Growth Ratios
| Growth Correlation 3m | -20.7% |
| Growth Correlation 12m | -73.9% |
| Growth Correlation 5y | 76.8% |
| CAGR 5y | 98.87% |
| CAGR/Max DD 3y | 1.25 |
| CAGR/Mean DD 3y | 2.78 |
| Sharpe Ratio 12m | -0.28 |
| Alpha | 0.05 |
| Beta | 0.812 |
| Volatility | 86.42% |
| Current Volume | 4293.9k |
| Average Volume 20d | 5809.3k |
| Stop Loss | 22 (-7.1%) |
| Signal | -1.00 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-171.5m TTM) > 0 and > 6% of Revenue (6% = -10.3m TTM) |
| FCFTA -0.11 (>2.0%) and ΔFCFTA -2.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -463.7% (prev 211.2k%; Δ -211.6kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.18 (>3.0%) and CFO -152.5m > Net Income -171.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 25.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (112.1m) change vs 12m ago 1.58% (target <= -2.0% for YES) |
| Gross Margin 100.1% (prev 32.11%; Δ 67.94pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover -19.32% (prev 0.05%; Δ -19.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1727 (EBITDA TTM -82.7m / Interest Expense TTM 48.0k) >= 6 (WARN >= 3) |
Altman Z'' -16.11
| (A) 0.96 = (Total Current Assets 827.0m - Total Current Liabilities 32.0m) / Total Assets 827.9m |
| (B) -0.72 = Retained Earnings (Balance) -599.1m / Total Assets 827.9m |
| (C) -0.09 = EBIT TTM -82.9m / Avg Total Assets 887.3m |
| (D) -18.50 = Book Value of Equity -599.3m / Total Liabilities 32.4m |
| Total Rating: -16.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 19.31
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -2.94% = -1.47 |
| 3. FCF Margin -51.20% = -7.50 |
| 4. Debt/Equity 0.00 = 2.50 |
| 5. Debt/Ebitda -0.01 = -2.50 |
| 6. ROIC - WACC (= -18.66)% = -12.50 |
| 7. RoE -19.98% = -2.50 |
| 8. Rev. Trend -4.37% = -0.33 |
| 9. EPS Trend -67.86% = -3.39 |
What is the price of VKTX shares?
Over the past week, the price has changed by -6.25%, over one month by -43.72%, over three months by -12.13% and over the past year by -64.69%.
Is Viking Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VKTX is around 32.53 USD . This means that VKTX is currently undervalued and has a potential upside of +37.32% (Margin of Safety).
Is VKTX a buy, sell or hold?
- Strong Buy: 10
- Buy: 7
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the VKTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88.8 | 274.8% |
| Analysts Target Price | 88.8 | 274.8% |
| ValueRay Target Price | 36.4 | 53.8% |
Last update: 2025-09-05 05:06
VKTX Fundamental Data Overview
CCE Cash And Equivalents = 33.9m USD (Cash And Short Term Investments, last quarter)
Revenue TTM is 0, using Net Income TTM -171.5m + Cost of Revenue 87.0k = -171.5m USD
P/B = 3.7926
P/EG = -0.03
Beta = 0.666
Revenue TTM = -171.5m USD
EBIT TTM = -82.9m USD
EBITDA TTM = -82.7m USD
Long Term Debt = 410.0k USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 468.0k USD (from shortTermDebt, last quarter)
Debt = 878.0k USD (Calculated: Short Term 468.0k + Long Term 410.0k)
Net Debt = -33.0m USD (from netDebt column, last quarter)
Enterprise Value = 2.98b USD (3.02b + Debt 878.0k - CCE 33.9m)
Interest Coverage Ratio = -1727 (Ebit TTM -82.9m / Interest Expense TTM 48.0k)
FCF Yield = -2.94% (FCF TTM -87.8m / Enterprise Value 2.98b)
FCF Margin = -51.20% (FCF TTM -87.8m / Revenue TTM -171.5m)
Net Margin = -100.1% (Net Income TTM -171.5m / Revenue TTM -171.5m)
Gross Margin = -100.1% ((Revenue TTM -171.5m - Cost of Revenue TTM 87.0k) / Revenue TTM)
Tobins Q-Ratio = -4.98 (set to none) (Enterprise Value 2.98b / Book Value Of Equity -599.3m)
Interest Expense / Debt = 2.73% (Interest Expense 24.0k / Debt 878.0k)
Taxrate = 21.0% (US default)
NOPAT = -82.9m (EBIT -82.9m, no tax applied on loss)
Current Ratio = 25.86 (Total Current Assets 827.0m / Total Current Liabilities 32.0m)
Debt / Equity = 0.00 (Debt 878.0k / last Quarter total Stockholder Equity 795.5m)
Debt / EBITDA = -0.01 (Net Debt -33.0m / EBITDA -82.7m)
Debt / FCF = -0.01 (Debt 878.0k / FCF TTM -87.8m)
Total Stockholder Equity = 858.5m (last 4 quarters mean)
RoA = -20.72% (Net Income -171.5m, Total Assets 827.9m )
RoE = -19.98% (Net Income TTM -171.5m / Total Stockholder Equity 858.5m)
RoCE = -9.65% (Ebit -82.9m / (Equity 858.5m + L.T.Debt 410.0k))
RoIC = -9.65% (NOPAT -82.9m / Invested Capital 858.5m)
WACC = 9.01% (E(3.02b)/V(3.02b) * Re(9.01%)) + (D(878.0k)/V(3.02b) * Rd(2.73%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.54%
Discount Rate = 9.01% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -87.8m)
EPS Correlation: -67.86 | EPS CAGR: -63.35% | SUE: -2.72 | # QB: 0
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: N/A | # QB: None
Additional Sources for VKTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle